In contrast to these findings, however, a similar retrospective analysis for a cohort of patients enrolled in the ALL-BFM95 trial did not find improved outcomes for patients with IKZF1 deletion receiving vincristine and steroid pulses during maintenance [86]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.